Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522141 · ClinicalTrials.gov registry record · Early Phase 1
Testing Self-Control as a Behavior Change Mechanism to Increase Physical Activity
A Early Phase 1 study, sponsored by Brandeis University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 81
- Enrollment target
NCT04522141: Completed Early Phase 1 study, sponsored by Brandeis University.
NCT04522141 is a Early Phase 1 study that has completed, run by Brandeis University. The registered enrollment target is 81 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04522141, a Early Phase 1 study, has completed, sponsored by Brandeis University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The goal of this study is to test self-control as a behavior change mechanism for physical activity and to investigate whether a smartphone-based self-control intervention can increase physical activity among sedentary middle-aged adults.
Primary Outcome
Average daily steps baseline week, average daily steps between pretest and posttest, and average daily steps between posttest and followup. A higher score means more steps.
Interventions
- BEHAVIORAL Control condition
- BEHAVIORAL Self-control intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-01-30 |
| Phase | Early Phase 1 |
What the finished NCT04522141 record still lists
NCT04522141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which Control condition is the first listed.
NCT04522141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04522141 about?
NCT04522141 is a clinical study titled "Testing Self-Control as a Behavior Change Mechanism to Increase Physical Activity". The goal of this study is to test self-control as a behavior change mechanism for physical activity and to investigate whether a smartphone-based self-control intervention can increase physical activity among sedentary middle-aged adults.
What is the current status of trial NCT04522141?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 81 participants. The study started on 2020-10-15. Estimated completion is 2022-01-30.
What interventions are being tested in trial NCT04522141?
The interventions under investigation include: Control condition (BEHAVIORAL), Self-control intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04522141?
This trial is sponsored by Brandeis University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04522141's enrollment target sits among peer trials
81 269th of 2000 higher than 1,730 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI